ArticleEMBO molecular medicine2026

Correction to: De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma.

Duo Xu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.